Challenges of the newer generation of Resorbable magnesium scaffolds: Lessons from failure mechanisms of the past generation.

[1]  T. Pilgrim,et al.  Magmaris resorbable magnesium scaffold versus conventional drug-eluting stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison. , 2022, Cardiovascular revascularization medicine : including molecular interventions.

[2]  R. Kobza,et al.  Long-Term Outcomes After Implantation of Magnesium-Based Bioresorbable Scaffolds—Insights From an All-Comer Registry , 2022, Frontiers in Cardiovascular Medicine.

[3]  L. Jiao,et al.  The Development of Design and Manufacture Techniques for Bioresorbable Coronary Artery Stents , 2021, Micromachines.

[4]  P. Serruys,et al.  Optimal Dual Antiplatelet Therapy Duration for Bioresorbable Scaffolds: an Individual Patient Data Pooled Analysis of the ABSORB Trials. , 2021, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  M. Joner,et al.  Effect of procedural technique on cardiovascular outcomes following second-generation drug-eluting resorbable magnesium scaffold implantation. , 2021, Cardiovascular revascularization medicine : including molecular interventions.

[6]  B. Yan,et al.  BIOSOLVE‐IV‐registry: Safety and performance of the Magmaris scaffold: 12‐month outcomes of the first cohort of 1,075 patients , 2020, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[7]  M. Joner,et al.  Preclinical investigation of neoatherosclerosis in magnesium-based bioresorbable scaffolds versus thick-strut drug-eluting stents. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[8]  D. Viladés,et al.  Magmaris bioresorbable stent: cardiac CT follow-up , 2020 .

[9]  S. Achenbach,et al.  Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis: The COMPARE-ABSORB Randomized Clinical Trial. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[10]  S. Saito,et al.  Comparison of Clinical Characteristics of Stent Thrombosis Between the Right Coronary Artery and the Left Coronary Artery　- A Subanalysis of the REAL-ST Registry. , 2019, Circulation journal : official journal of the Japanese Circulation Society.

[11]  A. Íñiguez,et al.  Magnesium-Based Resorbable Scaffold versus Permanent Metallic SirolimusEluting Stent in Patients with ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial. , 2019, Circulation.

[12]  K. McCutcheon,et al.  Magmaris resorbable magnesium scaffold for the treatment of coronary heart disease: overview of its safety and efficacy , 2019, Expert review of medical devices.

[13]  E. Cerrato,et al.  Magmaris™ resorbable magnesium scaffold: state-of-art review. , 2019, Future cardiology.

[14]  Aloke V. Finn,et al.  Fully bioresorbable vascular scaffolds: lessons learned and future directions , 2018, Nature Reviews Cardiology.

[15]  P. Serruys,et al.  Multislice computed tomography assessment of everolimus-eluting Absorb bioresorbable scaffolds in comparison with metallic drug-eluting stents from the ABSORB Japan randomised trial. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[16]  M. Joner,et al.  Preclinical evaluation of degradation kinetics and elemental mapping of first- and second-generation bioresorbable magnesium scaffolds. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[17]  R. Virmani,et al.  Understanding the Impact of Stent and Scaffold Material and Strut Design on Coronary Artery Thrombosis from the Basic and Clinical Points of View , 2018, Bioengineering.

[18]  Patrick W Serruys,et al.  Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary , 2018, European heart journal.

[19]  P. Teirstein,et al.  3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial. , 2017, Journal of the American College of Cardiology.

[20]  R. Virmani,et al.  Discontinuity: Is it a Major Cause of Scaffold Thrombosis? , 2017, Journal of the American College of Cardiology.

[21]  L. Räber,et al.  Mechanisms of Very Late Bioresorbable Scaffold Thrombosis: The INVEST Registry. , 2017, Journal of the American College of Cardiology.

[22]  P. Serruys,et al.  Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation: Analysis From the ABSORB Trials. , 2017, Journal of the American College of Cardiology.

[23]  R. Virmani,et al.  Comparison of Acute Thrombogenicity for Metallic and Polymeric Bioabsorbable Scaffolds: Magmaris Versus Absorb in a Porcine Arteriovenous Shunt Model , 2017, Circulation. Cardiovascular interventions.

[24]  M. Joner,et al.  Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[25]  S. Kische,et al.  Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[26]  Soo Teik Lim,et al.  Mechanical behavior of polymer-based vs. metallic-based bioresorbable stents. , 2017, Journal of thoracic disease.

[27]  J. Mehilli,et al.  Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[28]  J. Tijssen,et al.  Bioresorbable Scaffolds versus Metallic Stents in Routine PCI , 2017, The New England journal of medicine.

[29]  Patrick W Serruys,et al.  Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[30]  S. Venkatraman,et al.  Bioresorbable stents: Current and upcoming bioresorbable technologies. , 2017, International journal of cardiology.

[31]  Bernard Chevalier,et al.  Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial , 2016, The Lancet.

[32]  A. Schmermund,et al.  Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. , 2016, Journal of the American College of Cardiology.

[33]  R. Whitbourn,et al.  A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up. , 2016, Journal of the American College of Cardiology.

[34]  Heribert Schunkert,et al.  Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials , 2016, The Lancet.

[35]  Soo Teik Lim,et al.  Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial , 2016, The Lancet.

[36]  N. Weissman,et al.  Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[37]  W. Shimizu,et al.  Neoatherosclerosis: Coronary stents seal atherosclerotic lesions but result in making a new problem of atherosclerosis. , 2015, World journal of cardiology.

[38]  P. Teirstein,et al.  Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. , 2015, The New England journal of medicine.

[39]  F. Eberli,et al.  Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings. , 2015, Journal of the American College of Cardiology.

[40]  S. Cook,et al.  Optical Coherence Tomography Findings in Bioresorbable Vascular Scaffolds Thrombosis , 2015, Circulation. Cardiovascular interventions.

[41]  R. Virmani,et al.  Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. , 2015, European heart journal.

[42]  R. Virmani,et al.  Thrombogenicity and Early Vascular Healing Response in Metallic Biodegradable Polymer-Based and Fully Bioabsorbable Drug-Eluting Stents , 2015, Circulation. Cardiovascular interventions.

[43]  C. Hamm,et al.  Current status of bioresorbable scaffolds in the treatment of coronary artery disease. , 2014, Journal of the American College of Cardiology.

[44]  R. Virmani,et al.  Long-Term Safety of an Everolimus-Eluting Bioresorbable Vascular Scaffold and the Cobalt-Chromium XIENCE V Stent in a Porcine Coronary Artery Model , 2014, Circulation. Cardiovascular interventions.

[45]  Raimund Erbel,et al.  Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial , 2013, The Lancet.

[46]  Bernard Chevalier,et al.  First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study , 2012, Circulation. Cardiovascular interventions.

[47]  E. Edelman,et al.  Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug Coatings , 2011, Circulation.

[48]  Bernard Chevalier,et al.  Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. , 2011, Journal of the American College of Cardiology.

[49]  Bernard Chevalier,et al.  Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes , 2010, Circulation.

[50]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2009, The Lancet.

[51]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.

[52]  Raimund Erbel,et al.  Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial , 2007, The Lancet.

[53]  Karl-Heinz Waldmann,et al.  Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[54]  A Haverich,et al.  Left main coronary artery fistula exiting into the right atrium , 2003, Heart.

[55]  H. Uehata,et al.  Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. , 2000, Circulation.